DOI QR코드

DOI QR Code

Association Between Survivin Gene Polymorphisms and the Susceptibility to Colon Cancer Development in the Turkish Population

  • Yamak, Nesibe (Department of Medical Biology and Genetics, Institue of Health Science, Duzce University) ;
  • Yaykasli, Kursat Oguz (Department of Medical Genetics, Faculty of Medicine, Duzce University) ;
  • Yilmaz, Umit (The Institute of Experimental Medicine, Department of Molecular Medicine, Istanbul University) ;
  • Eroz, Recep (Department of Medical Genetics, Faculty of Medicine, Duzce University) ;
  • Uzunlar, Ali Kemal (Department of Medical Pathology, Faculty of Medicine, Duzce University) ;
  • Ankarali, Handan (Department of Statistics, Faculty of Medicine, Duzce University) ;
  • Sahiner, Cem (Department of Medical Pathology, Faculty of Medicine, Duzce University) ;
  • Baltaci, Davut (Department of Family Medicine, Faculty of Medicine, Duzce University)
  • Published : 2014.11.06

Abstract

Background: Colon cancer is one of the most common cancers worldwide. Apoptosis is a necessary physiological process for cell elimination which is very important both cellular homeostasis and cell proliferation and differantiation. Dysregulation can lead to uncontrolled cell growth and tumor development. Survivin, a member of the IAP family, plays a key role in promotion of cell proliferation as well as inhibition of apoptosis in cancer cells. The aim of this study was to investigate whether specific genetic polymorphisms of survivin could be associated with colon cancer development and progression in a Turkish population. Our study is the first to our knowledge to investigate the relationship between colon cancer risk and survivin gene polymorphisms. Materials and Methods: The relation between colon cancer and survivin -31 G/C (rs9904341), -241 C/T (rs17878467) and -625 C/G (rs8073069) polymorphism in promotor site of survivin gene associated with apoptosis was investigated using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: Individuals with -31C allele and CC genotype were found to have a higher risk of developing colon cancer (OR=13.4, p=0.01). The -241 CT genotype considerably increased the risk of colon cancer (OR=12.0, p=0.0001). However, there was no significant varaition of the survivin -625 C/G polymorphism among colon cancer patients and controls in our study. Conclusions: This study provides the first evidence that survivin -31 G/C and -241 C/T SNP significantly contribute to the risk of colon cancer in the Turkish population.

Keywords

Colon cancer;survivin;polymorphism;PCR-RFLP;susceptibility;Turkey

References

  1. Azcarate-Peril AM, Sikes M, Bruno-Barcena JM (2011). The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?. Am J Physiol Gastrointest Liver Physiol, 301, G401-24. https://doi.org/10.1152/ajpgi.00110.2011
  2. Al-Sohaily S, Biankin A, Leong R, et al (2012). Molecular pathways in colorectal cancer. J Gastroenterology and Hepatology, 27, 1423-31. https://doi.org/10.1111/j.1440-1746.2012.07200.x
  3. Altieri DC (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer, 3, 46-54. https://doi.org/10.1038/nrc968
  4. Altieri DC (2008). Survivin, cancer networks and pathwaydirected drug discovery. Nat Rev Cancer, 8, 61-70. https://doi.org/10.1038/nrc2293
  5. Altieri DC (2010). Survivin and IAP proteins in cell-death mechanism. Biochem J, 430, 199-205. https://doi.org/10.1042/BJ20100814
  6. Andric M, Nikolic N, Boskovic M, et al (2012). Survivin gene promoter polymorphism -31G/C as a risk factor for keratocystic odontogenic tumor development. Eur J Oral Sci, 120, 9-13. https://doi.org/10.1111/j.1600-0722.2011.00919.x
  7. Anne B B, Clive A (2007). Colorectal cancer. Clinical review. BMJ, 335, 715-8. https://doi.org/10.1136/bmj.39321.527384.BE
  8. Arslan UV, Ozmerdivenli R, Yaykasli KO, et al (2012). Investigation of TIMP2 Gene Polymorphisms Incidence in Patients with Breast Cancer. Eur J Basic Medical Sciences, 2, 101-105.
  9. Aynaci E, Coskunpinar E, Eren A, et al(2013). Association between survivin gene promoter -31 G/C and -644 C/T polymorphisms and non-small cell lung cancer. Genetics Molecul Res, 12, 3975-82. https://doi.org/10.4238/2013.February.28.9
  10. Borbely AA, Murvai M, Szarka K, et al (2007). Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol, 60, 303-6.
  11. Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, et al (1999). Carcinomas and other epithelial and neuroendocrine tumors of the large intestine. In: Gastrointestinal pathology an atlas and text. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 909-1068.
  12. Borges BN, Burbano RR, Harada ML (2011). Survivin -31 C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med, 11, 189-93. https://doi.org/10.1007/s10238-010-0122-5
  13. Chen J, Cui X, Zhou H, et al (2013). Functional promoter -31 G/C variant of survivin gene predict prostate cancer susceptibility among Chinese: a case control study. BMC Cancer, 13, 356. https://doi.org/10.1186/1471-2407-13-356
  14. Dai J, Jin G, Dong J, et al (2010). Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thoracic Oncol, 5, 11. https://doi.org/10.1097/01.JTO.0000372622.81561.0e
  15. Gazouli M, Tzanakis N, Rallis G, et al (2009). Survivin -31 G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis, 24, 145-150. https://doi.org/10.1007/s00384-008-0601-2
  16. Han CH, Wei Q, Lu KK, et al (2009). Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med, 2, 289-99.
  17. Jaiswal PK, Goel A, Mandhani A, et al (2012). Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep, 39, 5615-21. https://doi.org/10.1007/s11033-011-1366-1
  18. Jang JS, Kim KM, Kang KH, et al (2008). Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer, 60, 31-9. https://doi.org/10.1016/j.lungcan.2007.09.008
  19. Jemal A, Tiwari RC, Murray T, et al (2004). American Cancer Society. Cancer statistics, CA Cancer J Clin, 54, 8.
  20. Johnson ME, Howerth EW (2004). Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol, 41, 599-607. https://doi.org/10.1354/vp.41-6-599
  21. Li XB, Li SN, Yang ZH, et al (2013). Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese Population. DNA and Cell Biology, 5, 236-42.
  22. Kawata N, Tsuchiya N, Horikawa Y, et al (2011). Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer, 129, 1872-80. https://doi.org/10.1002/ijc.25850
  23. Kostic M, Nikolic N, Ilic B, Carkic J, Milenkovic S, Vukadinovic M (2013). Analysis of polymorphism in the survivin gene promoter as a potential risk factor for head and neck cancer development. Srp Arh Celok Lek, 141, 304-7. https://doi.org/10.2298/SARH1306304K
  24. Li DX, Zeng B, Xie LQ (2008). Expression and the clinical significance of survivin protein and b-catenin protein in primary hepatocellular carcinoma (HCC). J Mod Oncol, 16, 62-6.
  25. Li Y, Wang J, Jiang F, et al (2012). Association of polymorphisms in survivin gene with the risk of hepatocelluler carcinoma in Chinese Han population: a case control study. BMC Medical Genetics, 13, 1.
  26. Liu Y, Li L, Qi H, et al (2013). Survivin -31G>C polymorphism and gastrointestinal tract cancer risk: A meta-Analysis. Plos One, 8, 54081. https://doi.org/10.1371/journal.pone.0054081
  27. Ma F, Zhang H, Zhai Y, et al (2011). Functional polymorphism-31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among Chinese. Plos One, 6, 2.
  28. Macaron C, Leach HB, Burke C, et al (2014). Hereditary colorectal cancer syndromes and genetic testing. J Surg Oncol, [Epub ahead of print].
  29. Mace PD, Shirley S, Day CL (2010). Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differentiation, 17, 46-53. https://doi.org/10.1038/cdd.2009.45
  30. Riedl SJ, Renatus M, Schwarzenbacher R, et al (2001). Structural basis for the inhibition of caspase-3 by XIAP. Cell, 104, 791-800. https://doi.org/10.1016/S0092-8674(01)00274-4
  31. Montorsi M, Maggioni M, Falleni M, et al (2007). Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology, 54, 2040-4.
  32. Qiao, L, Wong BCY (2009). Targetting apoptozis as an approach for gastrointestinal cancer theraphy. Drug Resist, 12, 55-64. https://doi.org/10.1016/j.drup.2009.02.002
  33. Qin C, Cao Q, Li P, et al (2012). Functional promoter -31 G>C variant in survivin gene is associated with risk and progression of renal cell cancer in Chinese population. Plos One, 7, 1.
  34. Ryan BM, O'Donovan N, Duffy MJ (2009). Survivin: A new target for anti-cancer theraphy. Cancer Treatment Reviews, 35, 553-62. https://doi.org/10.1016/j.ctrv.2009.05.003
  35. Shike M, Winawer SJ, Greenwald PH, et al (1990). Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull WHO, 68, 377-85.
  36. Srinivasula SM, Ashwell JD (2008). IAPs: What's in a Name? Molecular Cell, 30, 25.
  37. Thompson CB (1995). Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-62. https://doi.org/10.1126/science.7878464
  38. Turgut T, Yasar M, Yaykasli KO, et al (2014). Evaluating genetic toxicity for patients with gastrointestinal cancers by sister chromatid exchange method. Eur J General Medicine, 11, 94-98. https://doi.org/10.15197/sabad.1.11.46
  39. Uchida H, Ando H, Maruyama K, et al (1998). Genetic Alterations of Mixed Hyperplastic Adenomatous Polyps in the colon and Rectum. Jpn. J Cancer Res, 89, 299-306. https://doi.org/10.1111/j.1349-7006.1998.tb00562.x
  40. Upadhyay R, Khurana R, Kumar S, et al (2011). Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol, 18, 880-7. https://doi.org/10.1245/s10434-010-1371-y
  41. Yaykasli KO, Kayikci MA, Yamak N, et al (2014). Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer, Turkish J Medical Sciences, 44, 1305.
  42. Verdecia MA, Huang H, Dutil E, et al (2007). Structure of the human antiapoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol, 7, 602-608.
  43. Wang YH, Chiou HY, Lin CT, et al (2009). Association between survivin gene promotor -31 G/C polymorphism and urothelial carcinoma risk in Taiwanese population. Urology, 73, 3. https://doi.org/10.1016/j.urology.2008.09.002
  44. Yang X, Xiong G, Chen X, et al (2009). Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol, 135, 1341-9. https://doi.org/10.1007/s00432-009-0575-7
  45. Yazdani N, Sayahpour FA, Haghpanah V, et al (2012). Survivin gene polymorphism association with papillary thyroid carcinoma. Pathology - Research and Practice, 208, 100-103. https://doi.org/10.1016/j.prp.2011.12.009

Cited by

  1. An Oncolytic Adenovirus Expressing SNORD44 and GAS5 Exhibits Antitumor Effect in Colorectal Cancer Cells vol.28, pp.8, 2017, https://doi.org/10.1089/hum.2017.041
  2. Evaluation of immunohistochemical expression of survivin and its correlation with −31G/C gene polymorphism in colorectal cancer pp.1860-1499, 2018, https://doi.org/10.1007/s00795-018-0204-0
  3. Polymorphisms of BIRC5 Gene is Associated with Chronic HBV Infection in Iranian Population pp.0974-0422, 2019, https://doi.org/10.1007/s12291-018-0805-3
  4. Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case–control studies pp.1437-7772, 2019, https://doi.org/10.1007/s10147-019-01408-y